Pazopanib, sold under the brand name Votrient, is a targeted cancer medication that can slow the growth of certain advanced kidney cancers and soft tissue sarcomas. Unlike traditional chemotherapy, it does not attack every rapidly dividing cell it can find. Instead, it blocks selected growth signals and interferes with the blood supply tumors need to expand.
That focused approach does not make pazopanib a lightweight medication. It carries a boxed warning for potentially severe liver injury and may also affect blood pressure, heart rhythm, wound healing, thyroid function, bleeding risk, and the gastrointestinal tract. Food, grapefruit, heartburn drugs, supplements, and several prescription medications can also change how much pazopanib reaches the bloodstream.
This guide explains what pazopanib is used for, how it is taken, what the tablets may look like, which interactions matter, and when side effects require urgent medical attention.
What Is Pazopanib?
Pazopanib is an oral tyrosine kinase inhibitor, often shortened to TKI. Tyrosine kinases are enzymes involved in cellular communication, growth, blood-vessel formation, and survival. Cancer cells can exploit these signaling systems like an office worker who discovers the password to the executive coffee machine.
The medication blocks several targets, including vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and c-KIT. By interfering with these pathways, pazopanib may reduce angiogenesis, which is the development of new blood vessels supplying a tumor, while also slowing cancer-cell growth.
Pazopanib is a prescription tablet. It is considered targeted therapy rather than conventional chemotherapy, although patients may casually refer to all anticancer medicines as “chemo.”
What Is Pazopanib Used For?
Advanced renal cell carcinoma
The FDA-approved indications include treatment of adults with advanced renal cell carcinoma, or RCC. Renal cell carcinoma is the most common major type of kidney cancer. “Advanced” generally means the cancer cannot be managed adequately with local treatment alone or has spread beyond its original location.
Pazopanib may be selected based on the cancer’s characteristics, previous treatments, a patient’s general health, expected side effects, and the availability of other targeted therapies or immunotherapy combinations. It is not automatically the preferred option for every person with kidney cancer.
Advanced soft tissue sarcoma
Pazopanib is also approved for adults with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcomas are a diverse group of cancers arising in tissues such as muscle, fat, nerves, tendons, and blood vessels.
The FDA label notes that effectiveness has not been demonstrated for adipocytic soft tissue sarcomas or gastrointestinal stromal tumors. Because sarcoma subtypes behave differently, treatment should be planned by an oncology team experienced with the exact diagnosis rather than treating “sarcoma” as one giant category.
Pazopanib Dosage and Administration
Standard adult dose
The usual recommended dosage is 800 milligrams once daily. With the branded 200-milligram tablets, that equals four tablets taken together. Treatment generally continues until the cancer progresses or side effects become unacceptable.
Pazopanib should be taken without food, at least one hour before eating or two hours after a meal. Food can approximately double exposure to the drug, so taking one dose with breakfast and the next on an empty stomach can create unpredictable medication levels. Consistency matters more than culinary improvisation.
How to take the tablets
Swallow pazopanib tablets whole with water. Do not crush, split, or chew them unless an oncology pharmacist gives different instructions for a specific product. Crushing a branded tablet has been shown to increase the rate and amount of absorption, potentially increasing toxicity.
Take each dose at approximately the same time every day. A phone alarm, medication calendar, or pill-tracking application can help, provided the tablets are stored according to pharmacy instructions.
What to do after a missed dose
If there are fewer than 12 hours before the next scheduled dose, skip the missed dose. Do not take two doses together to catch up. When the timing is uncertain, call the oncology clinic or dispensing pharmacist instead of conducting a home experiment in pharmacology.
Dose reductions and liver impairment
Dose interruptions or reductions are common when laboratory abnormalities or troublesome side effects develop. The reduction schedule differs between renal cell carcinoma and soft tissue sarcoma, so patients should never copy another person’s dosing plan.
For moderate hepatic impairment, the prescribing information recommends considering alternatives. If pazopanib is used, the labeled dose is reduced to 200 milligrams once daily. The medication is not recommended for severe hepatic impairment. Mild liver impairment may not require an initial adjustment, but laboratory monitoring remains essential.
Strong CYP3A4 inhibitors can raise pazopanib concentrations. When one cannot be avoided, the label recommends reducing Votrient to 400 milligrams daily. These changes must be directed by the prescribing team, not performed by removing a random number of tablets from tomorrow’s dose.
What Does Pazopanib Look Like?
According to the U.S. prescribing information, branded Votrient is supplied as a 200-milligram, film-coated, modified capsule-shaped tablet. The tablet may appear gray or pink and has “GS JT” debossed on one side.
Generic pazopanib tablets may have different colors, shapes, packaging, or imprints depending on the manufacturer. A pill should never be identified by color alone. Lighting, coating changes, and the fact that “small pink tablet” describes approximately half the average medicine cabinet make visual guessing unreliable.
Compare the imprint, strength, manufacturer, and pharmacy label. Contact the pharmacy before taking a tablet that looks unexpectedly different, is chipped, has an unreadable imprint, or arrived in damaged packaging.
Common Pazopanib Side Effects
The side-effect profile varies according to the cancer being treated, treatment duration, other medications, and individual health conditions. In the major renal cell carcinoma trial described in the FDA label, frequently reported reactions included diarrhea, high blood pressure, hair-color changes, nausea, reduced appetite, vomiting, fatigue, weakness, abdominal pain, and headache.
Diarrhea occurred in 52% of pazopanib-treated participants in that study, hypertension in 40%, hair-color changes in 38%, and nausea in 26%. These percentages describe a clinical-trial population; they do not predict exactly what one individual will experience.
Digestive effects
Diarrhea, nausea, vomiting, abdominal discomfort, appetite loss, taste changes, and weight loss can occur. Patients should report persistent symptoms early because dehydration can worsen fatigue, kidney stress, dizziness, and electrolyte abnormalities. The oncology team may recommend antidiarrheal or anti-nausea medication, hydration strategies, and nutrition support.
Fatigue and weakness
Cancer itself can cause fatigue, and pazopanib may add another layer. Sudden or severe exhaustion should not automatically be dismissed as “just treatment.” It may signal dehydration, infection, anemia, thyroid changes, heart dysfunction, liver injury, or another correctable problem.
Hair, skin, and hand-foot changes
Hair or skin may become lighter during treatment. Some patients develop rash, dryness, tenderness, thickened skin, or a hand-foot skin reaction affecting pressure points on the palms and soles. Early reporting can prevent mild irritation from advancing to painful cracking or difficulty walking.
Important Warnings and Serious Side Effects
Severe liver injury
Pazopanib carries a boxed warning for hepatotoxicity. Severe and fatal liver injury has occurred. Liver tests are generally obtained before treatment, during the early months, and periodically afterward. The FDA label specifies monitoring at weeks 3, 5, 7, and 9, during months 3 and 4, and subsequently as clinically indicated.
Contact the treatment team immediately for yellow skin or eyes, dark urine, unusual bruising, severe nausea, right-sided upper abdominal pain, reduced appetite, or marked fatigue. Liver enzyme elevations often occur early; most transaminase elevations reported in the label developed within the first 18 weeks.
High blood pressure and cardiovascular problems
Pazopanib can raise blood pressure, sometimes quickly. Blood pressure should be controlled before treatment and checked regularly afterward. Patients may be asked to keep a home log, especially during the first several weeks.
The medication may also contribute to QT prolongation, abnormal heart rhythms, reduced heart-pumping function, arterial blood clots, venous blood clots, heart attack, or stroke. Emergency evaluation is warranted for chest pain, fainting, sudden shortness of breath, one-sided weakness, speech difficulty, or a painful swollen leg.
Bleeding, gastrointestinal perforation, and fistula
Serious bleeding can occur. Warning signs include vomiting blood, black stools, bloody urine, coughing up blood, severe unexplained bruising, or bleeding that will not stop. Rarely, a hole or abnormal connection can develop in the stomach or intestines. Severe abdominal pain, fever, a rigid abdomen, or persistent vomiting requires urgent assessment.
Lung and neurological complications
Interstitial lung disease or pneumonitis has been reported and can be fatal. New or worsening cough, breathing difficulty, or unexplained shortness of breath should be reported promptly.
A rare condition called posterior reversible encephalopathy syndrome may cause severe headache, seizures, confusion, vision changes, or very high blood pressure. Despite the word “reversible,” it is an emergency, not an invitation to wait until Monday.
Other significant risks
Pazopanib can impair wound healing, cause protein to leak into the urine, reduce thyroid function, contribute to serious infections, or trigger tumor lysis syndrome in susceptible patients. Thrombotic microangiopathy, a dangerous disorder involving small blood vessels and blood cells, has also been reported.
Doctors may pause treatment before planned surgery and delay restarting it until healing is adequate. The exact timing depends on the procedure, wound, cancer status, and clinical judgment.
Pazopanib Drug and Food Interactions
CYP3A4 inhibitors and inducers
Pazopanib is metabolized mainly through CYP3A4. Strong inhibitors can raise its concentration and increase toxicity, while strong inducers can lower exposure and potentially reduce effectiveness.
Examples that may require special management include certain azole antifungals, macrolide antibiotics, seizure medications, rifampin, some heart-rhythm medicines, and selected antiviral drugs. This is not a complete interaction list, and the clinical significance differs among products.
Grapefruit and grapefruit juice can also increase exposure and should generally be avoided. St. John’s wort may lower drug levels and should not be used unless the oncology team explicitly approves it.
Heartburn and acid-reducing medications
Proton pump inhibitors and H2-receptor antagonists can reduce pazopanib absorption by raising stomach pH. In a drug-interaction study, esomeprazole decreased pazopanib exposure by approximately 40%.
The label advises avoiding gastric acid-reducing agents when possible. If treatment is necessary, clinicians may consider a short-acting antacid separated from pazopanib by several hours. Patients should not stop a prescribed ulcer or reflux medication without discussing the safest alternative.
Simvastatin and QT-prolonging medicines
Simvastatin used with pazopanib has been associated with a higher incidence of elevated liver enzymes. Pazopanib can also prolong the QT interval, so combining it with other QT-prolonging medications may increase rhythm-related risk.
Give the oncology pharmacist a complete list of prescription drugs, over-the-counter products, vitamins, powders, teas, gummies, and herbal supplements. “Natural” is a marketing category, not an interaction-free force field.
Pregnancy, Breastfeeding, and Fertility
Pazopanib can harm a developing fetus. Pregnancy testing is recommended for patients who could become pregnant before treatment begins. Females of reproductive potential should use effective contraception during treatment and for at least two weeks after the final dose.
Males, including those who have had a vasectomy, should use condoms with female partners of reproductive potential during treatment and for at least two weeks after the last dose. The medication may impair male or female fertility.
Breastfeeding is not recommended during pazopanib treatment or for two weeks following the final dose because of the potential for serious adverse effects in a nursing infant.
Monitoring During Treatment
Monitoring is a central part of pazopanib treatment, not an optional accessory. The care team may order liver panels, complete blood counts, electrolytes, thyroid testing, urinalysis, kidney-related testing, and blood-pressure measurements. Electrocardiograms or heart-function imaging may be appropriate for patients with cardiovascular risks.
Imaging studies are performed periodically to determine whether the cancer is shrinking, stable, or progressing. A dose reduction does not necessarily mean treatment has failed. In many cases, adjusting the dose allows a patient to remain on therapy while improving tolerability.
Call the oncology team before changing the dose, taking a new supplement, scheduling surgery, receiving another cancer therapy, or starting treatment for reflux, infection, blood pressure, or pain.
Practical Experiences With Pazopanib Treatment
Experiences with pazopanib are highly individual, but several practical patterns repeatedly appear in oncology education and day-to-day treatment management. The first is that the medication schedule can shape a person’s routine more than expected. Taking the tablets on an empty stomach sounds simple until breakfast, appointments, travel, nausea, and family meals all begin competing for the same two-hour window.
Many patients find it easier to choose one dependable daily time. An early-morning dose may work for someone who can wait an hour before breakfast. A bedtime dose may be more convenient for a person who stops eating several hours earlier. The best schedule is the one approved by the treatment team that can be followed consistently without turning every meal into a mathematics examination.
Another common experience is that side effects may arrive gradually rather than dramatically. Loose stools may become more frequent over several days. Food may taste metallic, bland, or simply “wrong.” Energy levels may drop, shoes may begin irritating tender feet, or home blood-pressure readings may creep upward. A symptom diary can help patients notice trends before they become severe.
Early communication often makes treatment easier. Patients sometimes hesitate to report symptoms because they fear the drug will be stopped. In reality, oncology teams have several options: supportive medication, hydration, dietary changes, temporary interruption, additional testing, or dose reduction. Quietly tolerating worsening diarrhea or dizziness rarely earns a medal; it mainly earns dehydration and an unscheduled clinic visit.
Food management is another practical challenge. Smaller meals, bland foods, adequate protein, and frequent fluids may be useful when appetite is low, although nutritional advice should be individualized. Strong smells can worsen nausea, while cold or room-temperature foods may be easier to tolerate. Taste changes can make favorite meals suddenly unappealing, so experimenting with different textures, mild seasonings, plastic utensils, or tart flavors may help when medically appropriate.
Blood-pressure monitoring can become part of the morning routine. Using a validated cuff, sitting quietly beforehand, and recording readings at similar times produces more useful information than checking immediately after climbing stairs or reading an alarming email. The clinic should provide thresholds for routine calls and emergency evaluation.
People also commonly notice emotional fluctuations. Waiting for scans, interpreting every ache, and managing visible changes such as lighter hair can be unsettling. Support groups, oncology social workers, counselors, and patient navigators can help patients and caregivers manage the workload that does not appear on a laboratory report.
The most useful lesson is that successful treatment is not merely swallowing tablets. It is a partnership involving medication timing, laboratory monitoring, symptom reporting, nutrition, blood-pressure management, and honest discussions about quality of life. Pazopanib may be an important anticancer therapy, but nobody receives bonus points for navigating it alone.
When to Seek Immediate Medical Care
Seek urgent medical attention for chest pain, fainting, severe breathing difficulty, signs of stroke, a seizure, uncontrolled bleeding, coughing or vomiting blood, black stools, severe abdominal pain, or a serious allergic reaction.
Contact the oncology team promptly for jaundice, dark urine, persistent vomiting or diarrhea, worsening cough, fever, painful hand-foot symptoms, major blood-pressure changes, rapidly increasing swelling, reduced urination, severe fatigue, confusion, or any symptom that is new, intense, or progressing.
Conclusion
Pazopanib is a targeted oral cancer therapy approved for advanced renal cell carcinoma and previously treated advanced soft tissue sarcoma. Its usual adult dose is 800 milligrams once daily on an empty stomach, but liver function, interacting medications, and treatment-related toxicity may require a lower dose or temporary interruption.
The medication can be effective, but it demands careful monitoring. Liver injury, hypertension, heart problems, bleeding, blood clots, impaired wound healing, gastrointestinal complications, lung inflammation, and pregnancy-related risks deserve particular attention. Taking pazopanib consistently, avoiding unapproved interactions, and reporting symptoms early can make treatment safer and more manageable.
